Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abivertinib - ACEA Therapeutics

Drug Profile

Abivertinib - ACEA Therapeutics

Alternative Names: A 610MA; Abivertinib maleate - ACEA Therapeutics; AC 0100; AC 0100 Maleate; AC-0010MA; ACEA-100610MA; EX-ACEA-0010MA; STI-5656

Latest Information Update: 07 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACEA Biosciences
  • Developer ACEA Therapeutics; Guangdong Provincial Peoples Hospital; Hangzhou ACEA Pharmaceutical Research; Sorrento Therapeutics
  • Class Acrylamides; Antineoplastics; Antivirals; Fluorobenzenes; Heterocyclic compounds; Piperazines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Epidermal growth factor receptor antagonists; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; Ras protein inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Marginal zone B-cell lymphoma; Prostate cancer
  • Phase I B-cell lymphoma
  • No development reported Lung cancer
  • Discontinued COVID 2019 infections

Most Recent Events

  • 05 Jul 2023 Safety and efficacy data from a phase IIa trial in Marginal zone B-cell lymphoma released by Sorrento Therapeutics
  • 05 Jul 2023 Sorrento Therapeutics plans a phase III trial for Marginal zone B-cell lymphoma in China
  • 28 Apr 2023 Sorrento Therapeutics suspends the phase II MAVERICK trial in Prostate cancer (Metastatic disease, Combination therapy, Hormone refractory, First-line therapy, Second-line therapy or greater) in USA (PO), due to company filed for chapter 11 bankruptcy (NCT05361915)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top